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The serological diagnosis of pemphigus relies on the detection of IgG autoantibodies 
directed against the epithelial cell surface by indirect immunofluorescence (IIF) on mon-
key esophagus and against desmoglein 1 (Dsg1) and Dsg3 by ELISA. Although being 
highly sensitive and specific tools, discrepancies can occur. It is not uncommon that sera 
testing positive by ELISA give a negative result by IIF and vice versa. This brings diag- 
no stic challenges wherein pemphigus has to be ascertained or ruled out, especially when 
no biopsy is available. We utilized the ability of anti-Dsg3 and anti-Dsg1 IgG to bind in 
specific desmosomal patterns to living cells to investigate these discrepancies between 
IIF and ELISA. Living cultured primary normal human keratinocytes were grown under 
differentiating conditions to induce adequate expression of Dsg1 and Dsg3, incubated 
with patient serum for 1 h, and then stained to visualize bound IgG. We investigated 
two different groups; sera from patients with a positive direct immunofluorescence (DIF) 
and inconsistent serological findings (n = 43) and sera with positive ELISA or IIF but with 
negative DIF (n = 60). As positive controls we used 50 sera from patients who fulfilled 
all diagnostics criteria, and 10 sera from normal human subjects served as negative 
controls. In the DIF positive group, IgG from 39 of the 43 sera bound to the cells in 
a desmosomal pattern while in the DIF negative group none of the 60 sera bound to 
the cells. This shows that for pemphigus patients, ELISA and IIF can be negative while 
anti-desmosomal antibodies are present and vice versa that ELISA and IIF can be posi-
tive in non-pemphigus cases. In absence of a biopsy for DIF, such findings may lead to 
misdiagnosis.
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inTrODUcTiOn
The autoimmune bullous disease pemphigus is caused by the loss of cell–cell adhesion between 
keratinocytes, induced by autoantibodies mainly directed against the desmosomal cadherins 
des moglein 1 (Dsg1) and/or 3 (Dsg3). The serological diagnosis of pemphigus relies on the 
demons tration of circulating anti-Dsg1 and anti-Dsg3 by ELISA and/or by indirect immunofluo-
rescence (IIF) on monkey esophagus substrate (1). In the pemphigus foliaceus (PF) subgroup, only 
TaBle 1 | Final diagnoses of patients in the direct immunofluorescence negative 
group.
Definite diagnosis no. of cases
Lichen planus 10
Bullous pemphigoid 7










Erosive pustular scalp dermatosis 1
Genital ulcer 1
Gingivitis 1
Graft versus host disease 1
Lichen planus pemphigoid 1
Lupus erythematosus 1




Final diagnoses were unavailable in 11 sera that were sent from different hospitals for a 
second opinion.
FigUre 1 | Groups’ characteristics and sampling number.
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antibodies against Dsg1 are present, whereas in pemphigus vul-
garis (PV) antibodies against Dsg3 are found in mucosal domi-
nant PV (mdPV), or together with anti-Dsg1 in mucocutaneous 
PV (mcPV) (2). Apart from antibodies to Dsg 1 and 3 also anti-
bodies to desmocollins (Dsc) 1, 2, and 3 are found, but these are 
more prevalent in atypical pemphigus diseases as paraneoplastic 
pemphigus, pemphigus herpetiformis, and pemphigus vegetans 
but are only found sporadically in classical PV and PF (3, 4). 
In addition to cadherins, dozens of other proteins were shown 
to be recognized by pemphigus IgG, including muscarinic and 
nicotinic acetylcholine receptors, the neonatal Fc receptor, and 
mitochondrial proteins but proof that these non-desmosomal 
antibodies have a role in acantholysis is lacking (5). Although 
being a highly sensitive and specific tool, the ELISA for Dsg1 and 
Dsg3 ectodomains can be positive without clinical or other labo-
ratory evidence for actual pemphigus, and a number of reports 
documenting a lack of concordance between positive ELISA and 
the final diagnosis of the patient can be found in the literature 
(6). Also, we recently reported the possibility of discrepancies for 
biopsy proven pemphigus patients, where we found that 9% of 
positive ELISA sera tested negative by IIF, while 6% of IIF posi- 
tive sera were negative by ELISA and 5% of pemphigus patient 
had completely negative serology (7). The latter can be due to a 
low level of antibodies that is not detectable by IIF or ELISA, to 
the cessation of antibody production while the skin is still loaded 
with IgG or that the disease is driven by non-desmosomal anti-
bodies. Inconsistent findings during the diagnostic process bring 
decision-making challenges wherein the diagnosis of pemphigus 
needs to be confirmed or ruled out, especially when no biopsy 
is available. Here, we employed as a new method the ability of 
pemphigus serum IgG to bind to living cultured keratinocytes 




From our database of the Center for Blistering Diseases in the 
Netherlands, we retrospectively selected sera from patients that 
had pemphigus in the differential diagnosis and at least one 
positive test, direct immunofluorescence (DIF), IIF on monkey 
esophagus, or Dsg ELISA. This retrospective study with leftover 
sera from diagnostic tests does not need approval of the ethics 
committee in the Netherlands. We included 103 sera and divided 
them in two groups according to the positive or negative result at 
DIF analysis for IgG deposits at the epithelial cell surface (ECS). 
Each group was subsequently branched in subgroups accord-
ing to the results obtained by IIF and by ELISA as routinely 
performed in the diagnostic work up of autoimmune bullous 
diseases (Figure  1). As double check, all sera were retested by 
both IIF on monkey esophagus and, to avoid false positives due 
to precursor epitopes, also by MBL MESACUP-2 Dsg ELISA. 
In the DIF negative group, 18 sera were positive for anti-Dsg1 
antibodies (median 36.5, Q1 30, Q3 43), and 14 sera were posi-
tive for anti-Dsg3 antibodies (median 34.5, Q1 29, Q3 45). Of the 
60 DIF negative patients, the final diagnosis was available for 
49 patients and included among others 10 cases of lichen planus 
and 7 cases of pemphigoid but no case of pemphigus (Table 1). 
For the validation of the in vitro assay, we used as positive controls 
sera from 50 PV and PF patients whose diagnosis had been ascer-
tained by concordance between DIF, IIF, ELISA, and clinical and 
histopathological findings. Sera from 10 healthy human subjects 
served as negative controls.
Keratinocyte Binding assay (KBa)
NHK were isolated from redundant healthy skin obtained from 
breast reduction surgery upon written informed consent and 
grown on glass coverslips in 24-well plates using CnT-Prime and 
CnT-Prime 2D Differentiation medium (CELLnTEC, Switzerland) 
at 37°C and 5% CO2. When shifted to 1.2 mM calcium medium, 
FigUre 2 | (a) Anti-Dsg3 IgG binding pattern to cultured keratinocytes showing desmosomal distribution at cell–cell contacts. Scale bar is 50 µm. 
(B) Anti-desmoglein 1 IgG binding pattern to cultured keratinocytes showing a desmosomal distribution at the cell periphery of differentiated cells. Scale  
bar is 50 µm.
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In the DIF+ groups 91% of the sera reacted with cultured kera- 
tinocytes by binding of IgG in a desmosomal pattern. Other 
patterns were not observed. In the IIF+ group, 10 of the 12 sera 
tested positive for desmosomal IgG binding (Table S1 in Sup-
plementary Material). In the ELISA+ group, all 26 sera tested 
positive for desmosomal binding. Interestingly, two sera (Table S1 
in Supplementary Material, #30, #32) positive for both anti-Dsg1 
and anti-Dsg3 IgG showed binding in the Dsg1 pattern only, 
which was in line with the clinical presentation of both patients 
that suggested PF instead of PV. IgG from one serum positive 
for anti-Dsg1 (Table S1 in Supplementary Material, #34) and 
one serum positive for anti-Dsg3 (Table S1 in Supplementary 
Material, #36) bound in a converse pattern to the cells; in the first 
case, erosive lesions limited to the foreskin were present, while 
in the second case both skin and oral involvement were noted. 
In the serologically negative group, two sera bound to the cells in 
the Dsg1 pattern (Table S1 in Supplementary Material, #39, #42) 
and in one case in the Dsg3 pattern (Table S1 in Supplementary 
Material, #43). None of the DIF− sera showed a desmosomal 
binding to cells. Results are summarized in the Table S2 in 
Supplementary Material.
Dsg1 and Dsg3 elisa
The sera that bound to cells but were negative by routine MBL 
ELISA were also assayed by a Dsg ELISA kit from another manu-
facturer. Although one serum tested positive with this kit, the 
other 12 remained negative. Complete ELISA results are listed 
in Table 2.
DiscUssiOn
Here, we developed a KBA as an additional test based on the ability 
of pemphigus IgG to bind to desmosomes of living keratinocytes. 
The KBA discriminates PV from PF but cannot discriminate 
between mdPV and mcPV as differentiated cells also express 
Dsg3. Although not qualitative it is a very sensitive assay as in the 
developing phase of the KBA, we found that when titers decrease 
and the ELISA turns negative the KBA remains positive (data 
not shown). Furthermore, similar to ELISA, the assay does not 
desmosomes are induced that initially contain Dsg3 but not Dsg1. 
After prolonged incubation, cells start to differentiate and to 
synthesize Dsg1. Hence, we used cells 4 days after calcium shift 
to test binding of patient IgG to desmosomal proteins. NHK on 
coverslips were incubated with 2.5% serum in culture medium 
for 1 h at 37°C after which the cells were fixed in 2% formaldehyde 
and stored frozen at −80°C until staining. Fixed keratinocytes 
were stained using DyLight488-labeled goat-anti-human IgG 
and DAPI for the nuclear staining. The KBA was scored positive 
for anti-Dsg1 antibodies if IgG bound only to large differentiated 
cells, and positive for anti-Dsg3 antibodies if IgG bound to all 
cells. If all cells bind IgG then it is impossible to assess the pres-
ence of concomitant anti-Dsg1 IgG as the large differentiated cells 
also express a high level of Dsg3. Hence, the term “not determi-
nable.” The KBA was scored negative if no binding to human IgG 
was observed. Coverslips were examined under a Leica DMRA 
fluorescence microscope and images acquired by a Leica DFC350 
FX digital camera (Leica, Germany).
Dsg1 and Dsg3 elisa
All sera were tested by the MESACUP-2 ELISA test for anti- 
Dsg1 and anti-Dsg3 antibodies (MBL, Japan). As a second means 
of comparison of the negative ELISA results of sera that tested posi-
tive in the KBA (n = 13), the anti-Dsg1 and anti-Dsg3 microplate 
ELISA (EUROIMMUN AG, Germany) was used. Both tests were 
performed according to the manufacturers’ respective protocols, 
and a cutoff value of 20 U/ml was used to define positivity.
resUlTs
Keratinocyte Binding assay
IgG from anti-Dsg3 containing sera binds to all keratinocytes in 
a typical desmosomal pattern (Figure 2A). IgG directed against 
Dsg1 binds in a desmosomal pattern to differentiated cells only 
that are easily recognizable as they are much larger than undif-
ferentiated cells and lie on top of them (Figure 2B). All PF sera 
and all PV sera of the positive control group bound to the cells in 
the expected patterns, and of the 10 normal human sera not one 
serum bound to the cells.
TaBle 3 | Values of sensitivity and specificity calculated for positive and negative 
controls, biopsy proven pemphigus patients and negative DIF patients groups.
group n KBa+ sensitivity (%) specificity (%)
Positive controls 50 50 100 –
D+ I+ E− 12 10 83.3 –
D+ I− E+ 26 26 100 –
D+ I− E− 5 3 60 –
NHS 10 0 – 100
D− I+ E− 28 0 – 100
D− I− E+ 32 0 – 100
D, direct immunofluorescence; I, indirect immunofluorescence; E, Dsg ELISA; NHS, 
normal human subjects; KBA, keratinocyte binding assay.
TaBle 2 | Alternative ELISA results for sera testing positive for keratinocyte 
binding but negative on first ELISA.
















D+ I+ E− 1 1 3 2 2 nd +
D+ I+ E− 2 3 2 2 3 nd +
D+ I+ E− 3 1 4 2 3 + −
D+ I+ E− 4 2 17 2 6 nd +
D+ I+ E− 5 19 13 2 15 nd +
D+ I+ E− 6 9 5 −14 −4 nd +
D+ I+ E− 7 8 14 3 8 nd +
D+ I+ E− 8 3 16 1 10 nd +
D+ I+ E− 10 6 5 34 45 nd +
D+ I+ E− 12 4 1 2 2 nd +
D+ I−E− 38 17 1 6 2 + −
D+ I− E− 41 1 0 −11 −7 + −
D+ I− E− 42 6 2 −10 −3 nd +
Values are expressed in U/mL.
Positive results are in bold.
D, direct immunofluorescence; I, indirect immunofluorescence; E, Dsg ELISA; EU, 
euroimmun; KBA, keratinocyte binding assay; nd, not determinable.
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discriminate between pathogenic and non-pathogenic antibodies 
as sera from patients in remission off-medication with positive 
anti-Dsg3 titers also bound to the cells (unpublished results).
Our results show that the KBA has a high correlation with the 
DIF, we tested in total here 93 sera with positive DIF and 97% of 
the sera bound to the cells in the specific desmosomal patterns 
(for details see Table 3). This is a higher sensitivity than IIF and 
ELISA which we recently calculated to be, respectively, 86 and 
89% (7). However, in contrast to IIF and ELISA, the KBA is labor 
intensive and also not quantitative and therefore not a suitable 
replacement for either IIF or ELISA. Of the 60 sera with negative 
DIF, none of the sera bound to the cells. As we reported before, 
a negative DIF is extremely rare in pemphigus and therefore 
pemphigus is not expected for this group, and indeed the final 
diagnosis that we could retrieve for 49 of these patients differed 
from pemphigus.
Interestingly, in two cases, we observed binding in a converse 
pattern than the antibodies’ profile determined by ELISA. In the 
first case (#34), only anti-Dsg1 IgG were detected by ELISA, but 
lesions were confined to the foreskin and the histopathology 
showed a suprabasal intraepidermal split, fitting a diagnosis of 
PV and presence of anti-Dsg3 antibodies as detected by KBA. 
The second case (#36) was a patient presenting with mucocutane-
ous involvement but both ELISA and KBA detected a different 
antibody profile than expected. The reason for this discrepancy 
is unclear.
A few reports in literature describe the existence of anti bodies 
against Dsg1 and/or Dsg3 in patients affected by skin con ditions 
other than pemphigus especially patients affected by lichen 
planus. Given explanations vary between these antibodies having 
an actual role in the pathogenesis of oral lichen planus or that 
they would be non-pathogenic (8–10). DIF was only performed 
in one of these studies, and both patients had no ECS IgG deposi- 
tion (10). Most of the our lichen planus patients had a DIF with 
fibrin deposition along the BMZ, but no deposition in ECS pat-
tern although in one case some irregular IgG deposition was seen 
in the epidermis. Four sera displayed anti-ECS antibodies and 
six were positive in ELISA, either for anti-Dsg1 or anti-Dsg3, or 
for both anti-Dsg1 and anti-Dsg3. Although positive in ELISA, 
they did not bind to cells. Seen that in actual active pemphigus, 
we clearly found binding when ELISAs became negative (values 
below 9) the question evolves to what these antibodies bind on 
the ELISA plates. As we used MESACUP-2 ELISA, it cannot be 
to the precursor form of Dsg. If they are non-pathogenic anti-
bodies, then they differ from non-pathogenic antibodies in pem- 
phigus patients in complete remission off therapy as these do 
bind to the cells. It could be that the antibodies are directed to 
a cryptotope that becomes unmasked in recombinant Dsg present 
on the ELISA plate. A last explanation is that they are just false 
positives caused by IgG binding to some other non-Dsg compo-
nent on the plate, although we then would have expected them 
to be positive in both ELISAs. Interestingly, 10 sera that bound 
to the cells (KBA+) were IIF positive but were negative in ELISA 
kits from different manufacturers. Some patients had positive 
ELISAs at start of the disease but these turned negative during 
the course of disease, while IIF stayed positive. Other patients 
never developed a positive ELISA. As the binding patterns were 
desmosomal the underlying protein must be desmosomal or 
desmosome associated. Prime candidates are Dsc and seen the 
binding of nine sera to all cells, Dsc3 would be the prime suspect. 
However, eight of these sera were included in a previous study 
on anti-Dsc3 antibodies, and only one of these was positive in 
an assay on transfected HEK cells that expressed the ectodomain 
of Dsc3 on the cell surface (4). In this same study, all eight sera 
tested also negative for anti-Dsc1 and anti-Dsc2 antibodies. 
Other antigens have been suggested to serve as pemphigus 
antigens including muscarinic and nicotinic acetylcholine recep-
tors, pemphaxin, and mitochondrial proteins (11–14). But these 
antigens are non-desmosomal and therefore cannot explain the 
observed desmosomal binding patterns. Despite being negative 
in the Dsg3 ELISA, we feel that Dsg3 is still the prime candidate 
as antigen. It is possible that we are dealing with low titer high 
avidity anti-Dsg3 antibodies here that have index values below 
the cutoff of the ELISA. We have observed patients with active 
disease that during titer monitoring occasionally had ELISA 
values just above the cutoff value but mostly, under still active 
disease, under the cutoff value (unpublished results).
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For daily practice of diagnosis, our binding assay results 
indicate that ELISA and IIF should be interpreted with care 
as they are positive in a considerable number of cases without 
other laboratory or clinical evidence of pemphigus. We esti-
mated that in our database for the period 1 January 2002 until 
1 January 2017, about 13% of patients with positive ELISAs for 
Dsg did not have pemphigus. Therefore, taking serum but no 
biopsy for diagnosis, which is a regularly encountered procedure 
in the consulting room, bears a risk to reach a false conclu-
sion. In our database, we found 32 sera with no concomitant 
biopsy that tested positive in either IIF or ELISA, while only 2 
(6%) were capable of binding to cells in the KBA (Table S3 in 
Supplementary Material).
The KBA we demonstrate here is extremely sensitive and 
reliable. For specialized laboratories, it can provide additional 
information in challenging cases where the diagnosis of pem-
phigus cannot be decisively confirmed nor ruled out by routine 
serological analysis. Furthermore, it is an additional research tool 
to investigate the nature of pemphigus antibodies.
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